INDUCTION HEALTHCARE GROUP PLC
Material new contract with North Central London Integrated Care System
Notice of Interim Results and Investor Presentation
London, UK - 30 October 2024: Induction Healthcare Group PLC ("Induction", the "Company", or the "Group"; AIM: INHC), a leading digital health platform driving transformation of healthcare systems, has signed a contract worth £1.5m to transform patient access to diagnostic tests across the North Central London Integrated Care System.
This project will deliver significant enhancements to Induction's integrated platform which will connect the Royal Free London NHS Foundation Trust, Whittington Health NHS Trust, and their corresponding Community Diagnostics Centres in Wood Green and Finchley. The platform will digitise diagnostic referrals and booking and will:
· Allow for integrated electronic referrals between the different electronic patient record systems used across the Integrated Care System ("ICS");
· Give Trusts direct access to Community Diagnostic Centre appointment slots to book tests directly for patients;
· Enable patients to manage and self-book their diagnostic tests, as well as access information about their visit;
· Collect data on patient 'no shows' to provide insight on initiatives to reduce missed appointments; and
· Allow smart scheduling (including same-day and multi-modality bookings) to be created and managed.
Induction CEO, Paul Tambeau, said: "Induction will be the first portal provider to integrate disparate electronic systems across a region to facilitate diagnostic tests for patients, while at the same time giving patients greater control over their care. Induction will own the platform IP. Digitising and individualising care pathways across an ICS aligns with our renewed corporate strategy, and we believe that this contract provides a basis for growth into the future. I look forward to providing a trading update with the Interim results on 5 November."
Induction is delivering this as a professional services contract to fund platform development, given that the functionality will be relevant to many other Integrated Care Systems. The majority of the revenue will be recognised in FY25.
Interim Results
Induction will release Interim Results for the 6 months ended 30 September 2024 on 5 November 2024. Paul Tambeau, CEO, and John McIntosh, CFO, will provide a live presentation via Investor Meet Company on 05 Nov 2024, 15:00 GMT. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 04 Nov 2024, 09:00 GMT, or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet INDUCTION HEALTHCARE GROUP PLC via: https://www.investormeetcompany.com/induction-healthcare-group-plc/register-investor. Investors who already follow Induction on the Investor Meet Company platform will automatically be invited.
Enquiries
Induction Christopher Samler, Chair Paul Tambeau, Chief Executive Officer |
+44 (0)7712 194092 +44 (0)7983 104443 | |
|
|
|
Singer Capital Markets (Nominated Adviser and Broker) | +44 (0)20 7496 3000 |
|
Philip Davies Jalini Kalaravy |
|
|
About Induction - www.inductionhealthcare.com
Induction (AIM: INHC) Induction delivers a suite of software solutions that transforms care delivery and the patient journey through hospital. Our system-wide applications help healthcare providers and administrators to deliver care at any stage remotely as well as face-to-face - giving the communities they serve greater flexibility, control and ease of access. Purpose-built for integration with leading Electronic Medical Record (EMR) platforms, our products offer immediate stand-alone value that becomes even greater when integrated with pre-existing systems.
Used at scale by national and regional healthcare systems, as well non-health government services, our applications are relied upon by hundreds of thousands of clinicians and millions of patients across almost every hospital in the British Isles.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.